Cancer Drug Prices: Hope Meets Harsh Reality

Government attempts to lower cancer medicine costs through trade margin caps on 137 drugs have yielded limited success. While some prices saw reductions, many expensive patented medications remain unaffordable for patients. Neeta Kumar's experience with a Rs 10 lakh treatment highlights the prohibitive cost of drugs like pembrolizumab, even after margin controls. Paresh Shah, though fortunate to have employer insurance, notes the financial strain on those without coverage.

Ribociclib, another key drug, continues to cost between Rs 65,000 and Rs 80,000 monthly for patients like lawyer Majida MA, despite previous government interventions. Analysis of revised prices shows an average reduction of less than 40%, with 159 formulations remaining unchanged, including all patented drugs.

Dr. Sarika Gupta emphasizes that even effective immunotherapies are often beyond reach, especially for patients with advanced or recurrent cancers who have already exhausted savings. Poonam Nanda's recurring battle with breast cancer, involving expensive treatments and patented drugs like Pivikto, illustrates the persistent financial ordeal.

The expiry of patents, as seen with palbociclib, can drastically reduce costs when generic competition emerges. However, for patented drugs without alternatives, patients like Lisha Jain face costs nearing Rs 17-18 lakh, including extensive travel and living expenses. The Organisation of Pharmaceutical Producers of India supports margin caps but stresses the need for better reimbursement mechanisms and collaboration to ensure true affordability.